RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
In their multiple-treatment meta-analysis, Andrea Cipriani and colleagues1 conclude that clinically important differences favour escitalopram and sertraline over other second-generation antidepressants. We published a similar study,2 with similar but not identical methods, and drew a different conclusion: benefits do not differ materially across the drugs. We believe that Cipriani and colleagues have overstated the evidence and ignored imprecision inherent in this analysis, thereby conveying overly precise findings from an approach fraught with uncertainties.
